Immunosuppressive regulatory cells in cancer immunotherapy: restrain or modulate?

IF 3.1 3区 生物学 Q3 CELL BIOLOGY Human Cell Pub Date : 2024-07-01 Epub Date: 2024-05-30 DOI:10.1007/s13577-024-01083-w
Yan Wu, Dongfeng Chen, Yang Gao, Qinggang Xu, Yang Zhou, Zhong Ni, Manli Na
{"title":"Immunosuppressive regulatory cells in cancer immunotherapy: restrain or modulate?","authors":"Yan Wu, Dongfeng Chen, Yang Gao, Qinggang Xu, Yang Zhou, Zhong Ni, Manli Na","doi":"10.1007/s13577-024-01083-w","DOIUrl":null,"url":null,"abstract":"<p><p>Immunosuppressive regulatory cells (IRCs) play important roles in negatively regulating immune response, and are mainly divided into myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs). Large numbers of preclinical and clinical studies have shown that inhibition or reduction of IRCs could effectively elevate antitumor immune responses. However, several studies also reported that excessive inhibition of IRCs function is one of the main reasons causing the side effects of cancer immunotherapy. Therefore, the reasonable regulation of IRCs is crucial for improving the safety and efficiency of cancer immunotherapy. In this review, we summarised the recent research advances in the cancer immunotherapy by regulating the proportion of IRCs, and discussed the roles of IRCs in regulating tumour immune evasion and drug resistance to immunotherapies. Furthermore, we also discussed how to balance the potential opportunities and challenges of using IRCs to improve the safety of cancer immunotherapies.</p>","PeriodicalId":49194,"journal":{"name":"Human Cell","volume":" ","pages":"931-943"},"PeriodicalIF":3.1000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Cell","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1007/s13577-024-01083-w","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/30 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Immunosuppressive regulatory cells (IRCs) play important roles in negatively regulating immune response, and are mainly divided into myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs). Large numbers of preclinical and clinical studies have shown that inhibition or reduction of IRCs could effectively elevate antitumor immune responses. However, several studies also reported that excessive inhibition of IRCs function is one of the main reasons causing the side effects of cancer immunotherapy. Therefore, the reasonable regulation of IRCs is crucial for improving the safety and efficiency of cancer immunotherapy. In this review, we summarised the recent research advances in the cancer immunotherapy by regulating the proportion of IRCs, and discussed the roles of IRCs in regulating tumour immune evasion and drug resistance to immunotherapies. Furthermore, we also discussed how to balance the potential opportunities and challenges of using IRCs to improve the safety of cancer immunotherapies.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
癌症免疫疗法中的免疫抑制调节细胞:抑制还是调节?
免疫抑制调节细胞(IRCs)在负性调节免疫反应中发挥着重要作用,主要分为髓源性抑制细胞(MDSCs)和调节性T细胞(Tregs)。大量临床前和临床研究表明,抑制或减少 IRCs 可有效提高抗肿瘤免疫反应。然而,一些研究也指出,过度抑制 IRCs 的功能是导致癌症免疫疗法副作用的主要原因之一。因此,合理调控 IRCs 对提高癌症免疫疗法的安全性和有效性至关重要。在这篇综述中,我们总结了近年来通过调节 IRCs 比例进行癌症免疫治疗的研究进展,并讨论了 IRCs 在调节肿瘤免疫逃避和免疫疗法耐药性方面的作用。此外,我们还讨论了如何平衡使用IRCs的潜在机遇与挑战,以提高癌症免疫疗法的安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Human Cell
Human Cell CELL BIOLOGY-
CiteScore
5.90
自引率
2.30%
发文量
176
审稿时长
4.5 months
期刊介绍: Human Cell is the official English-language journal of the Japan Human Cell Society. The journal serves as a forum for international research on all aspects of the human cell, encompassing not only cell biology but also pathology, cytology, and oncology, including clinical oncology. Embryonic stem cells derived from animals, regenerative medicine using animal cells, and experimental animal models with implications for human diseases are covered as well. Submissions in any of the following categories will be considered: Research Articles, Cell Lines, Rapid Communications, Reviews, and Letters to the Editor. A brief clinical case report focusing on cellular responses to pathological insults in human studies may also be submitted as a Letter to the Editor in a concise and short format. Not only basic scientists but also gynecologists, oncologists, and other clinical scientists are welcome to submit work expressing new ideas or research using human cells.
期刊最新文献
Generation of a human-induced pluripotent stem cell line from a retinitis pigmentosa patient carrying biallelic mutations in EYS gene. Pathogenesis and therapeutic strategies for neuropsychiatric lupus centered on innate immune activation. Human peritoneal CCR2LowCRIgHigh macrophage subset exhibits embryonic origin-like phenotypes. Extracellular vesicle-derived CDCP1 promotes chemoresistance and macrophage polarization in breast cancer. Ethanol-induced NINJ1 oligomerization might contribute to the lytic death of granulosa cells in PCOS.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1